SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Meta Expands AI Training With Employee Activity Tracking Tools 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
NEW YORK, March 22, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of PixarBio Corporation (OTC MKTS:PXRB) (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/pixarbio-corporation
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that PixarBio made false and/or misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) certain assertions in press releases, third party promotional materials, and PixarBio’s Form S-1 lacked accuracy; and (3) as a result, the Company’s public statements were materially false and misleading.
On January 23, 2017, the Securities and Exchange Commission announced the temporary suspension of PixarBio trading stating, in part, that “the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1.”
If you suffered a loss in PixarBio you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
